BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $93.67 Average PT from Brokerages

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-three brokerages that are presently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $93.67.

Several research firms recently weighed in on BMRN. Citigroup dropped their price target on BioMarin Pharmaceutical from $93.00 to $81.00 and set a "neutral" rating on the stock in a research report on Wednesday. StockNews.com raised shares of BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. TD Cowen lowered their price target on shares of BioMarin Pharmaceutical from $125.00 to $120.00 and set a "buy" rating for the company in a research report on Tuesday, August 6th. William Blair cut shares of BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a report on Wednesday. Finally, Wells Fargo & Company lowered their target price on shares of BioMarin Pharmaceutical from $115.00 to $90.00 and set an "overweight" rating for the company in a report on Tuesday, September 17th.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the stock. Innealta Capital LLC bought a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $25,000. nVerses Capital LLC bought a new position in BioMarin Pharmaceutical in the third quarter valued at about $28,000. BOKF NA purchased a new position in BioMarin Pharmaceutical in the second quarter worth about $31,000. Quent Capital LLC grew its stake in shares of BioMarin Pharmaceutical by 58.9% during the 2nd quarter. Quent Capital LLC now owns 391 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 145 shares during the period. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at about $47,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Trading Down 1.2 %

BioMarin Pharmaceutical stock traded down $0.79 during mid-day trading on Thursday, hitting $65.89. The company's stock had a trading volume of 1,839,720 shares, compared to its average volume of 1,848,847. The business has a 50 day moving average price of $76.08 and a 200-day moving average price of $80.94. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.05 and a quick ratio of 1.95. BioMarin Pharmaceutical has a 12 month low of $65.35 and a 12 month high of $99.56. The stock has a market cap of $12.51 billion, a price-to-earnings ratio of 62.32, a price-to-earnings-growth ratio of 0.81 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. The company had revenue of $746.00 million for the quarter, compared to analysts' expectations of $703.37 million. During the same quarter in the prior year, the company earned $0.26 earnings per share. The company's revenue was up 28.4% compared to the same quarter last year. As a group, analysts forecast that BioMarin Pharmaceutical will post 2.39 EPS for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.